Yesterday, the Interim President & CEO of Idexx Laboratories (IDXX), Jay Mazelsky, sold shares of IDXX for $2.58M.
Following Jay Mazelsky’s last IDXX Sell transaction on November 21, 2016, the stock climbed by 149.3%. In addition to Jay Mazelsky, 3 other IDXX executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Idexx Laboratories’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $620 million and quarterly net profit of $126 million. In comparison, last year the company earned revenue of $581 million and had a net profit of $109 million. The Company has a Price to Book ratio of 134.9111. IDXX’s market cap is $23.28B and the company has a P/E ratio of 57.76.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $289.00, reflecting a 7.9% upside.
The insider sentiment on Idexx Laboratories has been negative according to 72 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group; Water; Livestock, Poultry, and Dairy; and Other.
